Eriseld Krasniqi

10PUBLICATIONS
39CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 31, 2026
Gene mutant dosage is associated with prognosis and metastatic tropism in 60,000 clinical cancer samples.

|May 25, 2026
Gene mutant dosage is associated with prognosis and metastatic tropism in 60,000 clinical cancer samples.

|Dec 17, 2024
Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study.

Eriseld Krasniqi, Lorena Filomeno, Teresa Arcuri

|Aug 10, 2024
DNA Damage Response in Early Breast Cancer: A Phase III Cohort in the Phobos Study.

Eriseld Krasniqi, Cristiana Ercolani, Anna Di Benedetto

|May 08, 2024
HER2 mutation as an emerging target in advanced breast cancer.

Giulia Bon, Francesca Sofia Di Lisa, Lorena Filomeno

|Dec 11, 2022
Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration.

Eriseld Krasniqi, Frauke Goeman, Claudio Pulito

Pageof 2

Frequent Collaborators

3 joint publications

Patrizia Vici

2 joint publications

Giulio Caravagna

2 joint publications

Andrea Sottoriva

2 joint publications

Konstantin Bräutigam